Please Wait
Applying Filters...
menu
    • menu
    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-24

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Gentec Pharmaceutical Group is focused on manufacturing & developing APIs/HPAPIs, Advanced Intermediates & Fine Chemicals.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-17

    Virtual Booth

    Contact Supplier

    Menu

    Cenerimod

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Nxera Assigns Japan, APAC Rights For Cenerimod To Viatris
    Nxera Assigns Japan, APAC Rights For Cenerimod To Viatris

    27 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/28/3034436/0/en/Nxera-Pharma-Assigns-Japan-and-APAC-ex-China-Rights-to-Cenerimod-for-Autoimmune-Diseases-to-Viatris.html

    GLOBENEWSWIRE
    27 Feb 2025
    Share Share
    Idorsia, Viatris update collaboration for selatogrel, cenerimod
    Idorsia, Viatris update collaboration for selatogrel, cenerimod

    26 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/26/3032551/0/en/Idorsia-and-Viatris-update-their-collaboration-for-selatogrel-and-cenerimod.html

    GLOBENEWSWIRE
    26 Feb 2025
    Share Share
    Viatris Publishes Phase 2b CARE Study Data for Cenerimod
    Viatris Publishes Phase 2b CARE Study Data for Cenerimod

    18 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/viatris-announces-publication-of-phase-2b-care-study-data-for-cenerimod-in-lancet-rheumatology-302334364.html

    PR NEWSWIRE
    18 Dec 2024
    Share Share
    Viatris Presents Late Breaking Abstract On Cenerimod At APLAR Congress
    Viatris Presents Late Breaking Abstract On Cenerimod At APLAR Congress

    23 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/viatris-presents-late-breaking-abstract-on-cenerimod-at-the-26th-asia-pacific-league-of-associations-for-rheumatology-annual-congress-302229124.html

    PR NEWSWIRE
    23 Aug 2024
    Share Share
    Viatris Focusing on its Collabo with Idorsia, Ph 3 Selatogrel and Cenerimod
    Viatris Focusing on its Collabo with Idorsia, Ph 3 Selatogrel and Cenerimod

    27 Mar 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/viatris-hosts-rd-event-focusing-on-its-collaboration-with-idorsia-phase-3-assets-selatogrel-and-cenerimod-and-key-elements-of-its-pipeline-302100327.html

    PR NEWSWIRE
    27 Mar 2024
    Share Share